Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) has strategically expanded its leadership team, appointing Bradley Raudabaugh as Vice President of Marketing and Errol Gould, Ph.D., as Vice President of Medical Affairs. These appointments come as Tonix anticipates a decision from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for TNX-102 SL, a sublingual tablet formulation of cyclobenzaprine, for the management of fibromyalgia.
The FDA is expected to decide on the acceptance of the NDA in December 2024, with a potential decision on approval anticipated in August 2025. TNX-102 SL has been granted Fast Track designation by the FDA, underscoring the unmet need for effective fibromyalgia treatments.
Leadership Expansion to Support Potential Launch
Seth Lederman, M.D., CEO of Tonix Pharmaceuticals, emphasized the importance of these strategic hires, stating, "We have further strengthened our leadership team with these two strategic hires as we continue to develop our commercial strategies and enhance the potential of our pipeline products... Bradley’s experience in spearheading successful product launches and his deep commercial insights provide us a crucial asset as we prepare to receive a decision from the U.S. Food and Drug Administration (FDA) for our TNX-102 SL NDA in 2025."
Raudabaugh brings over 25 years of marketing, sales, and product planning experience, most recently serving as Vice President of Product Strategy at Axsome Therapeutics. Gould has over 25 years of experience in research and development and medical affairs, with a focus on neurology, pain, and sleep.
TNX-102 SL: A Potential Breakthrough for Fibromyalgia
Fibromyalgia is a chronic condition characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory, and mood issues. Affecting an estimated 2-4% of the adult population, predominantly women, fibromyalgia presents a significant healthcare challenge. Current treatments often provide limited relief, highlighting the need for new therapeutic options.
TNX-102 SL is designed for bedtime sublingual administration. If approved, TNX-102 SL would represent the first new drug for treating fibromyalgia in more than 15 years and the first member of a new class of analgesic drugs for this condition. The NDA submission was supported by data from two statistically significant Phase 3 studies demonstrating efficacy in managing fibromyalgia symptoms.
Broader Pipeline and Strategic Collaborations
Beyond TNX-102 SL, Tonix Pharmaceuticals is advancing a diverse pipeline of product candidates targeting central nervous system (CNS) disorders, immunology, rare diseases, and infectious diseases. This includes TNX-1300, a biologic in Phase 2 development for cocaine intoxication, and TNX-1500, a monoclonal antibody for the prevention of allograft rejection and treatment of autoimmune diseases.
Tonix has also secured a contract with the U.S. Department of Defense (DoD) for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections.
